Patient´s perspective: emotional impact of the COVID-19 pandemic in psoriasis patients treated with biological drugs and small molecules in real clinical practice

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/36445
• EU PAS number:
  EUPAS35712
• Study ID:
  36445
• Official title and acronym:
  Patient´s perspective: emotional impact of the COVID-19 pandemic in psoriasis patients treated with biological drugs and small molecules in real clinical practice
• DARWIN EU® study:
  No
• Study countries:
  Spain
• Study description:
  The current COVID-19 pandemic may have had an impact not only on patients' health, but also on their social behaviour and their perception of vulnerability resulting from exposure to immunosuppressive/immunomodulatory psoriatic drugs. We sought to clarify the status of these patients with respect to possible COVID-19 involvement and to detect changes in their treatment regimen, the reason why they made them as well as the influence in their social behaviour. We conducted a retrospective study and included 174 patient under biologics or small molecules during the onset and the development of the crisis. We found a not significant incidence of COVID-19 infection and we bring to light emotional impact of pandemic in this group of patients, as an increased worry about their immunosuppressed status has been evidenced. Individuals also took additional measures to protect themselves and looked for information on internet. COVID-19 pandemic has not only had an impact on health, but also on the emotional sphere of psoriatic patients.
• Study status:
  Finalised

Research institutions and networks

Institutions

Hospital Universitario Príncipe de Asturias

Study timelines

Date when funding contract was signed

Planned: 02/03/2020

Actual: 02/03/2020

Study start date

Planned: 09/03/2020

Actual: 09/03/2020

Date of final study report

Planned: 08/06/2020

Actual: 08/06/2020

Sources of funding

Pharmaceutical company and other private sector 

Non-for-profit organisation (e.g. charity)

EU institutional research programme

Other

More details on funding

Name of Pharmaceutical companies, Charities, Government body, Research councils, EU funding scheme, Other: not provided

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable